Page 16 - 2019 Annual Report | ECP
P. 16

    Mark N. Kirstein (Co-I) Cancer Center Support Grant NIH: National Cancer Institute
   Mark N. Kirstein (Co-I)
Innovative Drug Discovery Pipeline for Preclinical Children's Tumor Development of Novel Drugs Foundation/SYNODOS
     Mark N. Kirstein (Co-I) Novel Targeted Chemo/Immunotherapy Approach for NIH: National Cancer Institute Localized and Metastatic Prostate Cancer
     Voriconazole Therapeutic Drug Monitoring in Mark N. Kirstein (Co-I) Pediatric Hematopoietic Stem Cell Transplant
Patients
Hematology Oncology Pharmacist Association
     Michael Kotlyar (PI) Menthol Flavored E-cigarette Use During a Simulated ClearWay Minnesota Ban of Menthol Cigarettes
   Michael Kotlyar (PI)
Effect of Banning Menthol Flavorant on Cigarette and NIH: National Institute on Drug e-Cigarette Use Abuse
   A Randomized, Double-Blind, Placebo-Controlled
Ilo E. Leppik (PI) Study of the Safety and Efficacy of Intranasal PharmaNet, Inc.
Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters
     An Open-Label Safety Study of USL261 in the
Ilo E. Leppik (PI) Outpatient Treatment of Subjects with Seizure PharmaNet, Inc.
Clusters
   HDL Mimetic Peptide-Mediated Enhancement of
Ling Li (PI) Neurovascular Function to Mitigate Cerebral Amyloid NIH: National Institute on Aging
Angiopathy and Alzheimer's Disease
     Ling Li (PI) Dysregulation of Protein Prenylation in the NIH: National Institute on Aging Pathogenesis of Alzheimer's Disease
   Testing a Unique HDL Mimetic Peptide to Reverse
Ling Li (PI) ApoE4 Lipidation Deficiency and Alzheimer's NIH: National Institute on Aging
Neuropathology
   Susan E. Marino (PI), Angela K. Birnbaum (C0-PI), Richard C. Brundage (Consultant), Ilo Leppik (Co-I)
Characterizing and Predicting Drug Effect on Cognition
NIH: National Institute of Neurological Disorders and Stroke
     Susan E. Marino (PI) Assay Validation of Vinpocetin Stanford University
   Susan E. Marino (PI), Angela K. Birnbaum (Co-I)
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-Release Tacrolimus (EnvarsusĀ® XR)-Based Immunosuppression Regimen in Kidney Transplant Recipients
Veloxis Pharmaceutics
  15




































































   14   15   16   17   18